Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. Show More...
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 6.51 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -1.4 -2.85 -2.28 -1.63 Dividends USD Payout Ratio % * Shares Mil 9.0 9.0 12.0 18.0 Book Value Per Share * USD 3.4 2.62 Free Cash Flow Per Share * USD -1.22 Return on Assets % -56.42 -86.34 -66.48 -81.42 Financial Leverage (Average) 1.18 1.1 1.16 Return on Equity % -74.47 Return on Invested Capital % -75.92 Interest Coverage -2.86 -117.79 Current Ratio 3.11 7.02 11.45 7.47 Quick Ratio 3.1 6.48 11.13 7.32 Debt/Equity